Alpha-2 adrenergic agonists reduce opiate withdrawal (OW), but a limiting side effect of clonidine (CLON) is significant hypotension. Double-blind controlled investigations indicate that lofexidine (LOF), also an alpha-2 adrenergic agonist, produces significantly less hypotension than CLON, but displays similar efficacy. Our group has reported on a Phase II, 20 day open, two site (Phil, LA), inpatient study assessing the tolerability and preliminary efficacy of LOF (1.6 (n=9), 2.4 (n=9 Phil, n=13 LA), 4.0 (n=3) mg/day), and preliminary results of a shorter duration (11-14 days, pilot I) 3.2 (n=6) mg/day study (n = evaluable subjects) (SFN, Herman et al., 1999). This study was the first to utilize: a dose-response analysis of LOF, LOF doses > 2.6 mg/day, morphine for stabilization, and initial plateau LOF doses, with three phases: morphine stabilization, detoxification/LOF treatment, and no medication. The Phase II investigation is now complete, including results of two 3.2 mg/day studies (pilot I below)...